Drug discovery and p53.

Abstract excerpt

In the past two decades, the identification of commonly mutated oncogenes and tumour suppressor genes has driven an unprecedented growth in our understanding of the genetic basis of human cancer. Although oncogenes can clearly serve as classically defined drug targets whose inactivation by small molecules could place a brake on cancer cell proliferation, the restoration of mutated tumour suppressor gene activity...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Design
• Share to Molecular Mimicry
• Share to Protein Folding